StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the stock.
TherapeuticsMD Price Performance
NASDAQ:TXMD opened at $1.49 on Wednesday. TherapeuticsMD has a 12-month low of $0.70 and a 12-month high of $2.44. The stock’s 50 day simple moving average is $1.10 and its 200-day simple moving average is $1.13.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.39 million during the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative return on equity of 14.08%.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- What is the Euro STOXX 50 Index?
- Top 5 Stocks Hedge Funds Are Buying Right Now
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- The Basics of Support and Resistance
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
